Goldstein J L, Ho Y K, Basu S K, Brown M S
Proc Natl Acad Sci U S A. 1979 Jan;76(1):333-7. doi: 10.1073/pnas.76.1.333.
Resident mouse peritoneal macrophages were shown to take up and degrade acetylated (125)I-labeled low density lipoprotein ((125)I-acetyl-LDL) in vitro at rates that were 20-fold greater than those for the uptake and degradation of (125)I-LDL. The uptake of (125)I-acetyl-LDL and its subsequent degradation in lysosomes were attributable to a high-affinity, trypsin-sensitive, surface binding site that recognized acetyl-LDL but not native LDL. When (125)I-acetyl-LDL was bound to this site at 4 degrees C and the macrophages were subsequently warmed to 37 degrees C, 75% of the cell-bound radioactivity was degraded to mono[(125)I]iodotyrosine within 1 hr. The macrophage binding site also recognized maleylated LDL, maleylated albumin, and two sulfated polysaccharides (fucoidin and dextran sulfate) indicating that negative charges were important in the binding reaction. A similar binding site was present on rat peritoneal macrophages, guinea pig Kupffer cells, and cultured human monocytes but not on human lymphocytes or fibroblasts, mouse L cells or Y-1 adrenal cells, or Chinese hamster ovary cells. Uptake and degradation of acetyl-LDL via this binding site stimulated cholesterol esterification 100-fold and produced a 38-fold increase in the cellular content of cholesterol in mouse peritoneal macrophages. Although the physiologic significance, if any, of this macrophage uptake mechanism is not yet known, we hypothesize that it may mediate the degradation of denatured LDL in the body and thus serve as a "backup" mechanism for the previously described receptor-mediated degradation of native LDL that occurs in parenchymal cells. Such a scavenger pathway might account for the widespread deposition of LDL-derived cholesteryl esters in macrophages of patients with familial hypercholesterolemia in whom the parenchymal cell pathway for LDL degradation is blocked, owing to a genetic deficiency of receptors for native LDL.
研究表明,驻留小鼠腹腔巨噬细胞在体外摄取和降解乙酰化的(125)I标记的低密度脂蛋白((125)I-乙酰-LDL)的速率比摄取和降解(125)I-LDL的速率高20倍。(125)I-乙酰-LDL的摄取及其随后在溶酶体中的降解归因于一个高亲和力、对胰蛋白酶敏感的表面结合位点,该位点识别乙酰-LDL而非天然LDL。当(125)I-乙酰-LDL在4℃与该位点结合,随后将巨噬细胞升温至37℃时,75%的细胞结合放射性在1小时内降解为单[(125)I]碘酪氨酸。巨噬细胞结合位点还识别马来酰化LDL、马来酰化白蛋白以及两种硫酸化多糖(岩藻依聚糖和硫酸葡聚糖),表明负电荷在结合反应中很重要。大鼠腹腔巨噬细胞、豚鼠枯否细胞和培养的人单核细胞上存在类似的结合位点,但人淋巴细胞或成纤维细胞、小鼠L细胞或Y-1肾上腺细胞以及中国仓鼠卵巢细胞上不存在。通过该结合位点摄取和降解乙酰-LDL可使胆固醇酯化增加100倍,并使小鼠腹腔巨噬细胞中的胆固醇细胞含量增加38倍。尽管这种巨噬细胞摄取机制的生理意义(如果有的话)尚不清楚,但我们推测它可能介导体内变性LDL的降解,从而作为先前描述的实质细胞中发生的天然LDL受体介导降解的“备用”机制。这样一种清除途径可能解释了家族性高胆固醇血症患者巨噬细胞中LDL衍生胆固醇酯的广泛沉积,在这些患者中,由于天然LDL受体的遗传缺陷,实质细胞中LDL降解途径受阻。